Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Buy

Key Points

• Wall Street Zen upgraded Omeros to “buy” from “hold,” joining other bullish analysts. The stock has a “Moderate Buy” consensus rating and an average price target of $38.
• Omeros reported quarterly EPS of $0.02, beating the expected $0.27 loss, while revenue of $28.53 million exceeded the $12.69 million consensus estimate.
• Shares opened at $17.19 after recently trading near their 52-week high of $18.14; institutional investors own 48.79% of the company, while insiders own 10.50%.

Omeros (NASDAQ:OMER - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

Several other research firms have also recently issued reports on OMER. HC Wainwright reissued a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Zacks Research cut shares of Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. Weiss Ratings raised shares of Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $38.00.

Omeros Trading Down 0.9%

NASDAQ OMER opened at $17.19 on Friday. The company has a 50-day moving average price of $10.89 and a two-hundred day moving average price of $11.54. Omeros has a 52 week low of $3.94 and a 52 week high of $18.14. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 13.43 and a beta of 2.54.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, equities research analysts expect that Omeros will post -0.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Thomas J. Cable sold 7,500 shares of the firm's stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total transaction of $87,075.00. Following the completion of the sale, the director directly owned 35,067 shares in the company, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of Omeros

Large investors have recently added to or reduced their stakes in the business. UBS Group AG lifted its position in shares of Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock worth $38,180,000 after buying an additional 1,513,893 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Omeros by 85.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company's stock valued at $1,897,000 after acquiring an additional 82,646 shares during the last quarter. Corient Private Wealth LLC raised its stake in shares of Omeros by 13.0% in the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company's stock valued at $11,817,000 after acquiring an additional 79,263 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company's stock valued at $68,929,000 after acquiring an additional 666,357 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in Omeros by 8,259,600.0% in the 4th quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company's stock worth $1,419,000 after purchasing an additional 82,596 shares during the last quarter. 48.79% of the stock is owned by institutional investors.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros reported second-quarter earnings of $0.02 per share, substantially ahead of the expected $0.27 loss, while revenue of $28.53 million more than doubled the $12.69 million consensus estimate. The earnings beat was the primary catalyst for the recent advance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management highlighted a strong launch for YARTEMLEA, along with debt reduction and potential share repurchases. Analysts also pointed to reduced C5 competition as a favorable factor for the company’s commercial outlook. OMER Stock Soars After YARTEMLEA Momentum
• Positive Sentiment: H.C. Wainwright maintained its Buy rating and $33 price target, citing YARTEMLEA’s strong launch and a more favorable competitive environment. The target implies substantial potential upside if the commercial momentum continues. Omeros Buy Rating and $33 Price Target
• Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment could add governance and investment expertise, but its near-term financial impact is unclear. Omeros Appoints Joseph Schocken to Board
• Neutral Sentiment: Trading in OMER call options increased sharply, indicating heightened speculative interest and bullish positioning, but options activity alone does not confirm a sustained fundamental move.
• Negative Sentiment: H.C. Wainwright lowered its long-term EPS forecasts to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. Although the firm retained its Buy rating, the revisions signal some caution about the pace of future earnings growth.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source